Continue to site >
Trending ETFs

Name

As of 05/21/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$153.40

$1.18 B

0.00%

0.56%

Vitals

YTD Return

-2.9%

1 yr return

-3.6%

3 Yr Avg Return

-2.1%

5 Yr Avg Return

2.9%

Net Assets

$1.18 B

Holdings in Top 10

37.6%

52 WEEK LOW AND HIGH

$153.7
$132.50
$160.46

Expenses

OPERATING FEES

Expense Ratio 0.56%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover N/A

Redemption Fee N/A


Min Investment

Standard (Taxable)

N/A

IRA

N/A


Fund Classification

Fund Type

Exchange Traded Fund


Name

As of 05/21/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$153.40

$1.18 B

0.00%

0.56%

FBT - Profile

Distributions

  • YTD Total Return -2.9%
  • 3 Yr Annualized Total Return -2.1%
  • 5 Yr Annualized Total Return 2.9%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.23%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Quarterly

Fund Details

  • Legal Name
    First Trust NYSE Arca Biotechnology Index Fund
  • Fund Family Name
    First Trust Advisors L.P.
  • Inception Date
    Jun 19, 2006
  • Shares Outstanding
    9550002
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Roger Testin

Fund Description

The Fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the Index. The Fund, using an indexing investment approach, attempts to replicate, before fees and expenses, the performance of the Index. The Index is developed, maintained and sponsored by ICE Data Indices, LLC (the “Index Provider”). The Index Provider reserves the right to, at any time, change the number of stocks comprising the Index by adding or deleting one or more stocks, or replacing one or more stocks contained in the Index with one or more substitute stocks of its choice, if in the Index Provider's discretion such addition, deletion or substitution is necessary or appropriate to maintain the quality and/or character of the Index.The Index is an equal-dollar weighted index designed to measure the performance of 30 leading biotechnology companies. Biotechnology companies are designated as those classified within the Biotechnology sub-industry group of theICE Uniform Sector Classification schema. The Biotechnology subindustry group includes (i) the Biotech Therapeutics sub-industry:companies engaged in the research and development of therapeutic treatments(including companies in the trial phase of therapeutic development), but are not focused on the commercialization and mass production of pharmaceutical drugs and (ii) the Biotech Tools & Diagnostics sub-industry: companies engaged in the production and provisioning of tools, systems or processesthat enable biotechnology practices (including companies that provide assaying equipment, sequencing techniques or systems, DNA processing, orcellular processing). According to the Index Provider, in order to be eligible for inclusion in the Index, a common stock or depositary receipt must be listed on a qualifying U.S. securities exchange, and meet the sizeand liquidity standards of the Index. According to the Index Provider, eligible securities are then ranked in descending order based on the following factors. These three distinct ranks are then combined to yield one comprehensive rank based on their respective weights:a. 50%: Net sales (revenue) over the last 12 months;b. 25%: Ratio of net sales (revenue) to R&D (research and development) expenditures over the last 12 monthsc. 25%: Percentage change in R&D expenditures (over the last 12 months) from those three years prior.The highest ranked 30 securities are selected for inclusion in the Index. Additionally, the total number of Index constituents classified to the Biotech Tools & Diagnostics sub-industry is capped at 6 constituents. If the limit is reached, the lowest ranked Biotech Tools & Diagnostics constituents are replaced with the next highest ranked Biotech Therapeutics non-constituents until this rule is met. The securities selected for inclusion in the Index are equally weighted. Index composition changes during scheduled reconstitutions are also subject to certain buffers designed to limit turnover. The Fund may invest in companies with various market capitalizations.The Index is rebalanced and reconstituted quarterly and the Fund will make corresponding changes to its portfolio shortly after the Index changes are made public. The Index’s quarterly rebalance and reconstitution schedule may cause the Fund to experience a higher rate of portfolio turnover. The Fund will be concentrated in an industry or a group of industries to the extent that the Index is so concentrated. As of March 28, 2024, the Index was composed of 30 securities and the Fund had significant investments in health care companies, although this may change from time to time. The Fund’s investments will change as the Index changes and, as a result, the Fund may have significant investments in jurisdictions or investment sectors that it may not have had as of March 28, 2024. To the extent the Fund invests a significant portion of its assets in a given jurisdiction or investment sector, the Fund may be exposed to the risks associated with that jurisdiction or investment sector.
Read More

FBT - Performance

Return Ranking - Trailing

Period FBT Return Category Return Low Category Return High Rank in Category (%)
YTD -2.9% -19.3% 19.9% 93.83%
1 Yr -3.6% -18.8% 23.7% 90.12%
3 Yr -2.1%* -30.2% 12.5% 77.42%
5 Yr 2.9%* -4.9% 15.9% 87.59%
10 Yr 7.3%* 0.3% 13.9% 73.83%

* Annualized

Return Ranking - Calendar

Period FBT Return Category Return Low Category Return High Rank in Category (%)
2023 2.5% -12.6% 19.0% 57.41%
2022 -4.8% -53.9% 3.2% 10.97%
2021 -3.6% -39.6% 24.2% 66.45%
2020 13.0% -13.6% 178.2% 54.97%
2019 19.7% 3.8% 63.8% 59.26%

Total Return Ranking - Trailing

Period FBT Return Category Return Low Category Return High Rank in Category (%)
YTD -2.9% -19.3% 19.9% 93.83%
1 Yr -3.6% -18.8% 23.7% 90.12%
3 Yr -2.1%* -30.2% 12.5% 77.42%
5 Yr 2.9%* -4.9% 15.9% 87.59%
10 Yr 7.3%* 0.3% 13.9% 73.83%

* Annualized

Total Return Ranking - Calendar

Period FBT Return Category Return Low Category Return High Rank in Category (%)
2023 2.5% -12.6% 19.0% 75.93%
2022 -4.8% -53.9% 3.7% 20.00%
2021 -3.6% -33.9% 26.0% 83.23%
2020 13.0% -0.7% 180.6% 83.44%
2019 19.7% 4.6% 63.8% 86.67%

FBT - Holdings

Concentration Analysis

FBT Category Low Category High FBT % Rank
Net Assets 1.18 B 7.41 M 47.2 B 38.27%
Number of Holdings 31 23 420 95.68%
Net Assets in Top 10 484 M 2.19 M 20.5 B 47.53%
Weighting of Top 10 37.57% 18.1% 77.0% 78.40%

Top 10 Holdings

  1. Ultragenyx Pharmaceutical Inc 4.23%
  2. Grifols SA 4.19%
  3. ACADIA Pharmaceuticals Inc 4.14%
  4. Charles River Laboratories International Inc 3.74%
  5. IQVIA Holdings Inc 3.68%
  6. Moderna Inc 3.62%
  7. Bio-Techne Corp 3.53%
  8. Neurocrine Biosciences Inc 3.50%
  9. Mettler-Toledo International Inc 3.48%
  10. Alnylam Pharmaceuticals Inc 3.47%

Asset Allocation

Weighting Return Low Return High FBT % Rank
Stocks
100.01% 87.17% 106.13% 3.70%
Cash
0.10% 0.00% 34.44% 93.21%
Preferred Stocks
0.00% 0.00% 7.86% 65.43%
Other
0.00% -22.99% 23.31% 72.84%
Convertible Bonds
0.00% 0.00% 0.37% 59.87%
Bonds
0.00% 0.00% 12.39% 61.11%

Stock Sector Breakdown

Weighting Return Low Return High FBT % Rank
Healthcare
100.00% 59.26% 100.00% 30.57%
Utilities
0.00% 0.00% 0.00% 56.05%
Technology
0.00% 0.00% 22.69% 59.24%
Real Estate
0.00% 0.00% 5.89% 57.96%
Industrials
0.00% 0.00% 7.02% 59.24%
Financial Services
0.00% 0.00% 1.60% 71.97%
Energy
0.00% 0.00% 0.00% 56.05%
Communication Services
0.00% 0.00% 9.11% 59.24%
Consumer Defense
0.00% 0.00% 25.73% 60.51%
Consumer Cyclical
0.00% 0.00% 1.92% 57.96%
Basic Materials
0.00% 0.00% 7.16% 70.70%

Stock Geographic Breakdown

Weighting Return Low Return High FBT % Rank
US
100.01% 66.21% 104.41% 3.09%
Non US
0.00% 0.00% 28.58% 85.80%

FBT - Expenses

Operational Fees

FBT Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.56% 0.08% 4.28% 85.19%
Management Fee 0.40% 0.03% 1.25% 9.26%
12b-1 Fee 0.00% 0.00% 1.00% 11.54%
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

FBT Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

FBT Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FBT Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover N/A 0.00% 238.00% 22.00%

FBT - Distributions

Dividend Yield Analysis

FBT Category Low Category High FBT % Rank
Dividend Yield 0.00% 0.00% 6.24% 72.22%

Dividend Distribution Analysis

FBT Category Low Category High Category Mod
Dividend Distribution Frequency Quarterly Annual Annual Annual

Net Income Ratio Analysis

FBT Category Low Category High FBT % Rank
Net Income Ratio -0.23% -2.54% 1.85% 49.03%

Capital Gain Distribution Analysis

FBT Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Distributions History

View More +

FBT - Fund Manager Analysis

Managers

Roger Testin


Start Date

Tenure

Tenure Rank

Jun 19, 2006

15.96

16.0%

Roger F. Testin, CFA, was born in 1966. Mr. Testin earned a B.S. in Accounting from the University of Illinois and has an MBA in Finance from the University of Chicago. He has been with First Trust Advisors L.P. since 2001 and he is a Portfolio Manager and Senior Vice President. As Product Manager for the VA’s, SMA’s and International Managed Products, Mr. Testin shall be responsible for the daily implementation and execution of the strategies for these product vehicles on behalf of the Investment Committee.

Daniel Lindquist


Start Date

Tenure

Tenure Rank

Jun 19, 2006

15.96

16.0%

Daniel J. Lindquist, CFA, was born in 1970. Mr. Lindquist earned a B.A. in Business Economics from Wheaton College and has an MBA in Finance from the University of Chicago. He has been with First Trust Advisors L.P. since 2004 and is a Managing Director. Mr. Lindquist is the Chairman of the Investment Committee and is responsible for the overall supervision of the Separate Managed Accounts.

Jon Erickson


Start Date

Tenure

Tenure Rank

Jun 19, 2006

15.96

16.0%

Jon C. Erickson, CFA, was born in 1966. Mr. Erickson earned a B.S. in Computer Science from the University of Illinois and has an MBA from the University of Illinois in Finance. He has been with First Trust Advisors L.P. since 1994 and he is a Portfolio Manager and Senior Vice President. As the head of FTA’s Equity Research Group, Mr. Erickson shall be responsible for determining the securities to be purchased and sold by Funds that do not utilize quantitative investment strategies on behalf of the Investment Committee.

David McGarel


Start Date

Tenure

Tenure Rank

Jun 19, 2006

15.96

16.0%

David G. McGarel, CFA, was born in 1966. Mr. McGarel earned a B.S. in Accounting from the University of Notre Dame. He has been with First Trust Advisors L.P. since 1997 and he is a Managing Director, Chief Operating Officer and the Chief Investment Officer. As head of FTA’s Strategy Research Group, Mr. McGarel shall be responsible for developing and implementing quantitative investment strategies for those Funds that have investment policies that require them to follow such strategies, on behalf of the Investment Committee.

Stan Ueland


Start Date

Tenure

Tenure Rank

Nov 08, 2006

15.57

15.6%

Mr. Ueland joined First Trust Advisors as a Vice President in August 2005 and has been a Senior Vice President of First Trust and FTP since September 2012. At First Trust, he plays an important role in executing the investment strategies of each portfolio of exchange-traded funds advised by First Trust. Before joining First Trust, he was vice president of sales at BondWave LLC from May 2004 through August 2005, an account executive for Mina Capital Management LLC and Samaritan Asset Management LLC from January 2003 through May 2004, and a sales consultant at Oracle Corporation from January 1997 through January 2003.

Chris Peterson


Start Date

Tenure

Tenure Rank

Mar 18, 2016

6.21

6.2%

Chris A. Peterson, CFA was born in 1975. Mr. Peterson earned a B.S in Finance from Bradley University and has an MBA from the University of Chicago Booth School of Business with concentrations in Analytic Finance & Accounting. He has been with First Trust Advisors L.P. since 2000. As head of FTA’s Portfolio Advisor’s Strategy Research Group, Mr. Peterson shall be responsible for developing and implementing quantitative equity strategies on behalf of the Investment Committee.

Erik Russo


Start Date

Tenure

Tenure Rank

Dec 31, 2020

1.41

1.4%

Mr. Russo is a Vice President of First Trust. He is responsible for implementing the investment strategies of each portfolio of exchange-traded funds advised by First Trust in his role as a Portfolio Manager. Mr. Russo joined First Trust in January of 2010.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.87 0.25